GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

GSK has had another setback in its oncology business, after the FDA asked it to restrict use of its PARP inhibitor Zejula in ovarian, fallopian tube, or primary peritoneal cancer to patients with ...

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

The post hailed “promising results” from a trial of GSK’s PARP inhibitor niraparib in brain cancer patients; the drug, sold as Zejula, is currently approved as a maintenance treatment for ...

GSK reported core earnings of 59 cents per American ... Oncology sales rose 72%, driven by strong patient demand for Jemperli and Ojjaara Zejula sales fell 3% in the quarter.

Back in 2023, the FDA gave Johnson & Johnson’s Akeega—a fixed tablet of GSK’s PARP inhibitor Zejula and J&J’s Zytiga—and AstraZeneca and Merck’s Lynparza-Zytiga cocktail separate ...